Evidence map›Paper›PMID 20116937›Full record

ReviewPathologie-biologie2010

Pathogenesis of hepatitis B virus infection.

F V Chisari, M Isogawa, S F Wieland

Open access · greenAbstract readReview
In one paragraph

Review in Pathologie-biologie, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 184 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
184citing papers in PubMed, 1 pooled it
15.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

184 citing papers in PubMed, 1 synthesis or guideline pooled it, 417 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Review
  5. [Advancement in the role of exosomes for hepatitis B virus infection diagnosis and treatment: mechanisms and clinical applications].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026
    Review
  6. Hepatitis B Virus andViruses · 2025
    Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. mRNA-LNP vaccine-induced CD8Molecular therapy : the journal of the American Society of Gene Therapy · 2024
    Article
  17. Article
  18. Article
  19. Review
  20. Review

124 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

F V ChisariDepartment of Immunology and Microbial Science, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA. fchisari@scripps.edu
M Isogawa
S F Wieland
Scripps Research Institute · US

Funding

PATHOGENESIS OF HEPATITIS B VIRUS IN TRANSGENIC MICER01CA040489 · NCI · SCRIPPS RESEARCH INSTITUTE, THE · PI CHISARI, FRANCIS VINCENT · 1985 to 2010
$7.7M
PATHOGENESIS OF LIVER DISEASE IN HEPATITISR01AI020001 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI CHISARI, FRANCIS VINCENT · 1985 to 2012
$7.4M
MOLECULAR PATHOGENESIS OF HEPATOCELLULAR CARCINOMAR01CA054560 · NCI · SCRIPPS RESEARCH INSTITUTE · PI CHISARI, FRANCIS VINCENT · 1991 to 2003
$1.6M
PATHOGENESIS OF HEPATITIS B IN TRANSGENIC MICER37CA040489 · NCI · SCRIPPS RESEARCH INSTITUTE · PI CHISARI, FRANCIS VINCENT · 1990 to 1999
–
NCI NIH HHS CA40489NCI NIH HHS CA54560NCI NIH HHS R01 CA040489NCI NIH HHS R01 CA054560NCI NIH HHS R37 CA040489NIAID NIH HHS AI20001NIAID NIH HHS R01 AI020001
6 · The paper itself

Abstract

The adaptive immune response is thought to be responsible for viral clearance and disease pathogenesis during hepatitis B virus infection. It is generally acknowledged that the humoral antibody response contributes to the clearance of circulating virus particles and the prevention of viral spread within the host while the cellular immune response eliminates infected cells. The T cell response to the hepatitis B virus (HBV) is vigorous, polyclonal and multispecific in acutely infected patients who successfully clear the virus and relatively weak and narrowly focussed in chronically infected patients, suggesting that clearance of HBV is T cell dependent. The pathogenetic and antiviral potential of the cytotoxic T lymphocyte (CTL) response to HBV has been proven by the induction of a severe necroinflammatory liver disease following the adoptive transfer of HBsAg specific CTL into HBV transgenic mice. Remarkably, the CTLs also purge HBV replicative intermediates from the liver by secreting type 1 inflammatory cytokines thereby limiting virus spread to uninfected cells and reducing the degree of immunopathology required to terminate the infection. Persistent HBV infection is characterized by a weak adaptive immune response, thought to be due to inefficient CD4+ T cell priming early in the infection and subsequent development of a quantitatively and qualitatively ineffective CD8+ T cell response. Other factors that could contribute to viral persistence are immunological tolerance, mutational epitope inactivation, T cell receptor antagonism, incomplete down-regulation of viral replication and infection of immunologically privileged tissues. However, these pathways become apparent only in the setting of an ineffective immune response, which is, therefore, the fundamental underlying cause. Persistent infection is characterized by chronic liver cell injury, regeneration, inflammation, widespread DNA damage and insertional deregulation of cellular growth control genes, which, collectively, lead to cirrhosis of the liver and hepatocellular carcinoma.

Indexed as

Adaptive ImmunityAnimalsCarcinoma, HepatocellularHepatitis BHepatitis B, ChronicHepatitis B virusHumansImmunity, CellularImmunity, HumoralLiver CirrhosisLiver NeoplasmsMiceMice, TransgenicT-LymphocytesT-Lymphocytes, Cytotoxic

Identifiers

PMID20116937
PMCPMC2888709
OpenAlexW2011555137

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.